Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Top Cited Papers
Open Access
- 22 September 2016
- journal article
- Published by American Society of Hematology in Blood
- Vol. 128 (12), 1562-1566
- https://doi.org/10.1182/blood-2016-02-699850
Abstract
Key Points: A total of 38% of patients who achieved CR (13 of 34) on brentuximab vedotin have remained in remission for >5 years and may be cured. Nine of the 13 patients (9% of all enrolled patients) have remained in long-term remission without a consolidative allogeneic transplant.Keywords
This publication has 18 references indexed in Scilit:
- Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantLeukemia & Lymphoma, 2013
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphomaAnnals of Hematology, 2011
- Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin LymphomaTransplantation and Cellular Therapy, 2008
- Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2008
- Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell TransplantHematology-American Society Hematology Education Program, 2008
- Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30Blood, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin ConjugatesPublished by Elsevier BV ,2006
- Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimenBone Marrow Transplantation, 2005